Coming May 2025
Get Early Access
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
26 employees
Jumpcode Genomics: Revolutionizing sequencing technology for global research in disease and oncology.
HQ
Founded
2015
Jumpcode Genomics, founded with a mission to revolutionize next-generation sequencing (NGS) technology, aims to enhance research capabilities in fields such as infectious disease, oncology, and consumer genomics. Their core vision is to improve sensitivity, reduce costs, simplify workflows, and eliminate bias in sequencing processes. The company offers a range of products including the Single Cell RNA Boost Kit, DepleteX® Human DNA Depletion Kit, and CRISPRclean RNA Prep, which are designed to optimize single-cell analysis, microbiome studies, and whole transcriptome profiling.
Notable figures affiliated with Jumpcode Genomics include leading researchers and scientists who have contributed to advancements in genomic technologies. The company has secured investments from prominent venture capital firms, bolstering its capacity for innovation. Key achievements include the development and patenting of their CRISPRClean technology, which has been widely adopted by researchers globally. Jumpcode Genomics has significantly impacted the field of genomics by providing tools that enhance the accuracy and efficiency of NGS, thereby advancing scientific understanding and potential therapeutic applications.
Operating Status
Active
Ownership Type(s)
Venture Capital
Main Product(s)
Genomics
Technology
Biotech
Tags
Biotech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Jumpcode Genomics founded?
Jumpcode Genomics was founded in 2015.
Where is Jumpcode Genomics's headquarters located?
Jumpcode Genomics's headquarters is located in San Diego, CA, US.
When was Jumpcode Genomics's last funding round?
Jumpcode Genomics's most recent funding round was for $21M (USD) in January 2021.
How many employees does Jumpcode Genomics have?
Jumpcode Genomics has 26 employees as of Feb 5, 2024.
How much has Jumpcode Genomics raised to-date?
As of July 05, 2023, Jumpcode Genomics has raised a total of $23.5M (USD) since Jan 20, 2021.
Add Comparison
Total Raised to Date
$23.5M
USD
Last Update Jan 20, 2021
Last Deal Details
$21M
USD
Jan 20, 2021
Series B
Current Employees
26
Last updated: Feb 5, 2024
No location information available for this company.
Locations
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts